Catalog No.S8028 Synonyms: XR9576

Tariquidar Chemical Structure

Molecular Weight(MW): 646.73

Tariquidar is a potent and selective noncompetitive inhibitor of P-glycoprotein with Kd of 5.1 nM in CHrB30 cell line, reverses drug resistance in MDR cell Lines. Phase 3.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 15 Publications

4 Customer Reviews

  • Effects of LEV alone, or in combination with MDRIs, on the migration of L3 stage H. contortus Kirby (A) and WAL (B) larvae; LEV alone shown with solid lines and closed symbols, IVM plus MDRIs shown as dashed lines and open symbols. The concentration of each MDRI in g/mL is shown as subscript after the MDRI name. Each data point represents mean ± SE, n = 9 (pooled data from three experiments,
    each with assays in triplicate); Asc: ascorbic acid, Zq: zosuquidar, Tq: tariquidar.

    Vet Parasitol, 2015, 211(1-2):80-8.. Tariquidar purchased from Selleck.

  • Mutations of the polar residues Y307, Q725 and Y953 to alanine, cysteine and phenylalanine (Y953F only) were tested for their effect on the modulation of basal ATPase activity of P-gp by drugs. Basal activity of cysless WT and mutant P-gps was taken as zero, inhibition was calculated as percentage of the basal activity and shown with downward bars (negative values), while stimulation was calculated as percentage of the basal activity and shown with upward bars (positive values). Bars are colored black for cysless WT or triple A (Y307A/Q725A/Y953A) while they are grey for the single mutants (Y307A/C, Q725A/C, Y953A/C/F). At least three experiments were carried out with duplicate samples for each mutant with indicated compounds, and errors bars denote the standard deviations.

    Biochem Pharmacol, 2016, 101:40-53.. Tariquidar purchased from Selleck.

  • viability of parental and resistant A549 and SW480 cells treated with PU-H71 (PU), puromycin (Puro), tariquidar and combinations of tariquidar with PU-H71 and puromycin for four days.

    Oncotarget, 2017, 8(5):7678-7690. Tariquidar purchased from Selleck.

  • DEX protects L-02 cells from TRAIL-induced apoptosis by upregulating P-gp. Apoptosis was evaluated using a TUNEL assay, and the number of TUNEL-positive cells in each group were counted. (A) Representative photomicrographs of the TUNEL assay. L-02 cells were divided into six groups based on their treatment regimens, (a) control untreated group, (b) pretreated with 10 µM DEX for 24 h, followed by incubation with TRAIL for 24 h, (c) pretreatment with 10 µM DEX for 24 h, followed by incubation with TRAIL and 25 nM TQD for 24 h, (d) pretreated with 10 µM DEX for 24 h, followed by incubation with TRAIL and 50 nM TQD for 24 h, (e) pretreated with 10 µM DEX for 24 h, followed by incubation with TRAIL and 100 nM TQD for 24 h, and (f) incubated with TRAIL for 24 h. All the groups were treated with TRAIL for the induction of apoptosis, with the exception of the control group. Magnification, ×200. (B) Quantitative analysis of the levels of apoptosis. Data are presented as the mean ± standard deviation. *P<0.05. DEX, dexamethasone; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TQD, tariquidar; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.

    Mol Med Rep, 2015, 12(6):8093-100.. Tariquidar purchased from Selleck.

Purity & Quality Control

Choose Selective P-gp Inhibitors

Biological Activity

Description Tariquidar is a potent and selective noncompetitive inhibitor of P-glycoprotein with Kd of 5.1 nM in CHrB30 cell line, reverses drug resistance in MDR cell Lines. Phase 3.
P-gp [1]
(CHrB30 cells)
5.1 nM(Kd)
In vitro

Tariquidar displays high-affinity binding to P-gp with Bmax of 275 pmol/mg. Tariquidar shows non-competitive interaction with the P-gp substrates vinblastine and paclitaxel. Tariquidar increases the steady-state accumulation of these cytotoxics in CHrB30 cells to levels observed in non-P-gp-expressing AuxB1 cells with EC50 of 487 nM. Tariquidar is able to inhibit the vanadate-sensitive ATPase activity of P-gp by 60-70%, with potent IC50 values of 43 nM. [1] Tariquidar may inhibit other resistance mechanisms at higher concentrations. 1 μM Tariquidar abrogates ABCG2 (BCRP)-mediated resistance to camptothecins in vitro. [2] Tariquidar potentiates the cyto-toxicity of several drugs including doxorubicin, paclitaxel, etoposide, and vincristine; complete reversal of resistance is achieved in the presence of 25- 80 nM Tariquidar. In MC26, a murine colon carcinoma cell line with intrinsic chemoresistance, the doxorubicin IC50 is fivefold lower in the presence of 0.1 μM Tariquidar (36 vs 7 nM). In murine mammary carcinoma, human small-cell lung carcinoma and human ovarian carcinoma cell lines with acquired chemotherapeutic resistance (EMT6/AR1.0, H69/LX4 and 2780 AD), the in vitro doxorubicin IC50 is 22-150-fold lower in the presence of 0.1 μM Tariquidar. P-gp inhibition persists for 23 h after removal of Tariquidar from the culture system. [3] Tariquidar restored the cyto-toxicity of doxorubicin and vinblastine in the National Cancer Institute (NCI)/ADRRES multicellular tumor spheroid model derived from the MCF7WT breast cancer cell line. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDCK cells M{Cx[GZ2dmO2aX;uJIF{e2G7 M2Lr[|MxKG2rboO= Mk\VRYN1cX[rdImgZZQhSkOUUDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBOTEONIHPlcIx{KHW|aX7nJJJpd2SjbXnu[UAyOjNiYYOgd5Vje3S{YYTlJIlv[3WkYYTl[EBnd3JiM{CgcYlveyCycnnvdkB1dyC|dXLzeJJifGViYXTkbZRqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BjgSCobIXvdo9u\XS{aXOgZY5idHm|aYOsJGVEPTB;MD6wNUDPxE1? M3LpelI{Ozd2OEey
EMT6/AR1.0 cells NYPpZY1NTnWwY4Tpc44h[XO|YYm= MV:xJIg> Mmn6TY5pcWKrdHnvckBw\iCvb4Xz[UBR\3BiaX6gSW1VPi:DUkGuNEBk\WyuczDh[pRmeiBzIHjyJIJ6KGSjdX7vdpVjcWOrbjDhZ4N2dXWuYYTpc44h[XO|YYmsJGlEPTB;MD6wOlQh|ryP MlHxNVgxQDNyM{S=
human CEM/VLB500 cells MnjZSpVv[3Srb36gZZN{[Xl? NFfl[mY{KGSjeYO= NFfmWYpT\X[ncoPhcEBw\iCSLXfwMY1m\GmjdHXkJI12dHSrZIL1[{Bz\XOrc4ThcoNmKHSxII\pcoJt[XO2aX7lJIlvKGi3bXHuJGNGVS:YTFK1NFAh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IILld4F7fXKrbjDhd5NigSxiRVO1NF0xNjB4ODFOwG0> NU[1NI44OTd|OUm5PVA>
A2780 cells NEXiXWVHfW6ldHnvckBie3OjeR?= MnHON|AhdWmwcx?= NHHJZXNKdmirYnn0bY9vKG:oIHj1cYFvKFCpcDDpckBCOjd6MDDj[YxteyCjZoTldkA{OCCvaX7zJIJ6KEixZXPod5QhOzN|NEKgZZN{[XluIFnDOVA:OC5zMkW4PUDPxE1? NFXDe|cyQDB6M{CzOC=>
human KBV1 cells NFmyS3JHfW6ldHnvckBie3OjeR?= M2X1OVExKG2rboO= MlL3TY5pcWKrdHnvckBw\iCDQlPCNUBqdiCqdX3hckBMSlZzIHPlcIx{KGGodHXyJFExKG2rboOgZpkhS2GuY3Xpck1CVSCvaXPyc5Bt[XSnIHHzd4F6NCCLQ{WwQVAvOjJ|IN88US=> M2ny[FI1QTByNkiz
human MCF7/Topo cells NVi0ZYU6TnWwY4Tpc44h[XO|YYm= MnzQTY5pcWKrdHnvckBw\iCDQlPHNkBmgHC{ZYPz[YQhcW5iaIXtZY4hVUOINz;Uc5BwKGOnbHzzJIJ6KEixZXPod5QhdWmlcn;wcIF1\SCjc4PhfUwhUUN3ME2wMlUzPiEQvF2= M2Tp[|IyPTdyMkiy
MCF7 MX cells NWHrVmdDTnWwY4Tpc44h[XO|YYm= NELte49KdmirYnn0bY9vKG:oIFLDVnAh\XiycnXzd4VlKGmwIF3DSlchVVhiY3XscJMh[nliSH;lZ4h{fCB|M{O0NkB{fGGrbnnu[{whUUN3ME2wMlY5KM7:TR?= Mn7ONVk6OzJ7NkC=
human HFE cells MknyR5l1d3SxeHnjxsBie3OjeR?= Mn7UO|IhcA>? NYT4WIRDS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUE[HIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NU4zQCEQvF2= NIKxe2ozPjF7N{G2NC=>
human HCT116 cells NH:1PG9EgXSxdH;4bYPDqGG|c3H5 MYW0PEBp MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xNk42KM7:TR?= M33NSlI3OTl5MU[w
human SW620 cells NVnaTlZpS3m2b4TvfIlkyqCjc4PhfS=> MYq0PEBp MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTW|YzOCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUK1JO69VQ>? MVeyOlE6PzF4MB?=
human SW620/AD300 cells MW\DfZRwfG:6aXRCpIF{e2G7 MXO0PEBp MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTW|YzOC:DREOwNEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTJ3IN88US=> MXiyOlE6PzF4MB?=
human CCD-18Co cells Mn7UR5l1d3SxeHnjxsBie3OjeR?= NYPBUohyPDhiaB?= NXvaXZpMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0OGLUG4R48h[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1{NTFOwG0> MWOyOlE6PzF4MB?=
human KB-V1 cells NYqweoFVTnWwY4Tpc44h[XO|YYm= M3\1WVIxOCCwTR?= MXjJcohq[mm2aX;uJI9nKFBvZ4CgbY4hcHWvYX6gT2IuXjFiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gdohw\GGvaX7lJFEzOyCjY3P1cZVt[XSrb36gZZQhOjByIH7N MkT2NlE3PTd{N{G=

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
MRP7 ; 

PubMed: 23393594     

HEK/MRP7 cells were treated with 0.3 µM tariquidar for different periods of time. The subcellular localization of MRP7 was analyzed by immunofluorescence. MRP7 staining is shown in green. DAPI (blue) counterstains the nuclei.

In vivo Tariquidar (2- 8 mg/kg p.o.) is found to significantly potentiate the antitumor activity of doxorubicin (5 mg/kg, i.v.) against MC26 murine colon carcinoma in vivo. In human carcinoma xenografts, coadministration of XR9576 (6 -12 mg/kg p.o.) fully restored the antitumor activity of paclitaxel, etoposide, and vincristine against two highly resistant MDR human tumor xenografts (2780AD, H69/LX4) in nude mice. [3]


Kinase Assay:


- Collapse

Steady-state drug accumulation assay:

AuxB1 and CHrB30 cells are grown to confluency in 12-well (24 mm) tissue culture dishes and the steady-state accumulation of [3H]-vinblastine is measured. Accumulation is initiated by the addition of 0.1 μ Ci [3H]-vinblastine and unlabelled vinblastine to a final concentration of 100 nM . The accumulation of [3H]-paclitaxel is measured using 0.1 μ Ci [3H]-paclitaxel and unlabelled drug to a final concentration of 1 μM . Cells are incubated in a reaction volume of 1 mL for 60 min at 37 ℃ under 5% CO2 in order to reach steady-state. The effect of the modulators XR9576 on [3H]-ligand accumulation is investigated in the concentration range 10-9 - 10-6 M. Modulators are added from a DMSO stock giving a final solvent concentration of 0.2 % (v/v). Following cell harvesting, accumulated drug is measured by liquid scintillation counting and normalized for cell protein content. Plots of amount accumulated as a function of modulator concentration are fitted with the general dose-response equation: Y={(a-b)/(1+(X/c)d)}+bWhere: Y=response; a=initial response; b=final response; c=EC50 concentration; d=slope value; X=drug concentration.
Cell Research:


- Collapse
  • Cell lines: Murine mammary carcinoma cell line MDR EMT6/AR1.0
  • Concentrations: ~100 nM Tariquidar
  • Incubation Time: 4 days
  • Method:

    Cells are seeded into 96-well plates at 800/well, in 100 μL of medium and incubated for 4 h at 37 ℃. Varying concentrations of modulator or solvent control (50 μL/well) are subsequently added and incubated for an additional 1 h before the addition of the cytotoxic drug. The cytotoxic drug (50 μL) is added to give a range of final concentrations in quadruplicate wells. After incubation for an additional 4 days, cell proliferation of adherent cells is assessed using the sulforhodamine B assay.

    (Only for Reference)
Animal Research:


- Collapse
  • Animal Models: Murine colon carcinoma xenografts MC26
  • Formulation: 5% (w/v) D-( 1)-glucose (dextrose) solution
  • Dosages: 8 mg/kg
  • Administration: Coadministration of Tariquidar (p.o.) with doxorubicin (5 mg/kg, i.v.)
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 52 mg/mL (80.4 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% Propylene glycol+5% Tween 80+65% D5W
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 646.73


CAS No. 206873-63-4
Storage powder
in solvent
Synonyms XR9576

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01663545 Completed -- Epilepsies Partial National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) July 31 2012 --
NCT01547754 Terminated -- HIV-Associated Cognitive Motor Complex National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC) January 9 2012 --
NCT01386476 Completed -- Drug Resistance National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC) June 15 2011 --
NCT00082368 Completed Drug: Tariquidar|Drug: Tc-94m Sestamibi Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 16 2004 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you please give me more specific and detailed information of how to dissolve and use this compound (S8028) for in vivo studies?

  • Answer:

    Tariquidar in 30% Propylene glycol, 5% Tween 80, 65% D5W at 30mg/ml will be a suspension or emulsion. If you are going to administrate the compound by oral gavage, it is fine. We also have test some vehicles for Tariquidar for i.p injection, and it is soluble in 5% DMSO+45% PEG 300+ddH2O at 2mg/ml clearly. When preparing the solution, please dissolve the compound in DMSO clearly first, then add PEG. After they mixed well, then dilute with water.

P-gp Signaling Pathway Map

Related P-gp Products

Tags: buy Tariquidar | Tariquidar supplier | purchase Tariquidar | Tariquidar cost | Tariquidar manufacturer | order Tariquidar | Tariquidar distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID